Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

Pembrolizumab Approved in Europe for Adult and Pediatric Relapsed/Refractory Classical Hodgkin Lymphoma

March 17th 2021

The European Commission has approved an expanded label for pembrolizumab for use as a single agent in the treatment of select adult and pediatric patients aged 3 years and older who have relapsed/refractory classical Hodgkin lymphoma.

NICE Recommends Against Olaparib for Metastatic Prostate Cancer

March 8th 2021

The United Kingdom’s National Institute for Health and Care Excellence will not recommend olaparib for the treatment of patients with hormone-relapsed, metastatic prostate cancer that harbors BRCA1 or BRCA2 mutations that has progressed on abiraterone acetate or enzalutamide.

Teclistamab Shows Continued Promise in Relapsed/Refractory Multiple Myeloma

March 8th 2021

Teclistamab demonstrated encouraging clinical activity, along with a tolerable safety profile, in patients with relapsed/refractory multiple myeloma.

Maintenance Lenalidomide Safe, Should Be Continued in Patients With Myeloma Who Contract COVID-19

March 5th 2021

Maintenance treatment with lenalidomide was found to be a safe treatment for patients with multiple myeloma who are diagnosed with COVID-19, supporting use of the immunomodulatory drug in this patient population.

Melphalan Triplets Elicit Responses, Are Safe in Relapsed/Refractory Multiple Myeloma

March 5th 2021

The triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib demonstrated encouraging clinical activity and was well tolerated in patients with heavily pretreated relapsed/refractory multiple myeloma.

Ixazomib Triplets Show Efficacy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

March 4th 2021

Ixazomib-based triplet regimens as induction therapy elicited higher rates of efficacy compared with ixazomib/dexamethasone alone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma.

Zanubrutinib Approved in Canada for Waldenström Macroglobulinemia

March 2nd 2021

Health Canada has approved the BTK inhibitor zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Dostarlimab Gets Positive EU Opinion in Recurrent or Advanced MSI-H Endometrial Cancer

February 26th 2021

February 26, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion to dostarlimab as a treatment for patients with recurrent or advanced microsatellite instability–high/mismatch repair deficient endometrial cancer who have progressed on or following platinum-based chemotherapy.

Cabozantinib/Nivolumab Approaches EU Approval for Frontline Advanced RCC

February 26th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the combination of cabozantinib plus nivolumab for use as a frontline treatment in patients with advanced renal cell carcinoma.

Dr. Kulasinghe on Identifying COVID-19–Associated Gene Signatures Through Spatial Transcriptomics

February 26th 2021

Arutha Kulasinghe, PhD, discusses identifying COVID-19–associated gene signatures through spatial transcriptomics.

Dr. Lavery on Cancer Care in Ireland Amidst the COVID-19 Pandemic

February 26th 2021

Anita Lavery, MD, MRCP, discusses the current state of cancer care during the COVID-19 pandemic in Ireland.

Dr. Garassino on COVID-19 Vaccine Distribution to Patients With Cancer in Italy

February 25th 2021

Marina Garassino, MD, discusses the distribution of the coronavirus disease 2019 vaccine to patients with cancer in Italy.

Dr. Kulasinghe on Cancer Care During the COVID-19 Crisis in Australia

February 19th 2021

Arutha Kulasinghe, PhD, discusses cancer care during the coronavirus disease 2019 pandemic in Australia.

Pamrevlumab May Address Unmet Need for Locally Advanced Pancreatic Cancer

February 17th 2021

February 17, 2021 – Pamrevlumab, a first-in-class inhibitor of connective tissue growth factor activity, is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) in a phase 3 trial for patients with unresectable locally advanced pancreatic cancer, a population in need of new options.

Fedratinib Approved in Europe for Newly Diagnosed and Previously Treated Myelofibrosis

February 9th 2021

February 9, 2021 - The European Commission has granted a full marketing authorization for fedratinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytopenia myelofibrosis who have not received JAK inhibitors or who have received ruxolitinib.

Teaching an Old Dog New Tricks: Repurposing Cancer Drugs to Combat COVID-19

February 5th 2021

February 4, 2021 - In response to the coronavirus disease 2019 pandemic, investigators have turned to tried-and-true cancer drugs to see whether they can be used to combat the virus.

Selinexor Approved in Israel for Multiple Myeloma, DLBCL

February 4th 2021

February 4, 2021 — The Israeli Ministry of Health has approved selinexor for the treatment of patients with multiple myeloma or diffuse large B-cell lymphoma.

Gilteritinib Receives Conditional Approval in China for FLT3+ AML

February 4th 2021

February 4, 2021 - The China National Medical Products Administration has granted a conditional approval to gilteritinib for use in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation detected by a validated test.

Ceralasertib/Durvalumab Combo Shows Efficacy in NSCLC Following Anti–PD-L1 Therapy

February 3rd 2021

February 3, 2021 - The combination of ceralasertib plus durvalumab improved overall response rate in patients with non‒small cell lung cancer who progressed on an anti-PD-1/PD-L1 therapy.

Larotrectinib Elicits Early Clinical Activity in NTRK Fusion–Positive Lung Cancer

February 2nd 2021

February 2, 2021 — Larotrectinib was found to elicit high response rates, durable responses, and to extend survival benefit in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.